Aldevron Breakthrough Blog: mRNA

Streamlining mRNA Production

Seeking guidance for a big investment

Messenger RNA (mRNA) based drugs and vaccines make up a new class of medicine showing tremendous promise. Compared to established drug and vaccine technologies, mRNA has the potential to reach patients faster by being easier to develop and produce. 

Read More

CDMOs, Expertise and Experience

Considering the processes of mRNA manufacturing

Similar to a comedian developing a stand-up routine around the latest trends, a Chief Scientific Officer (CSO) drives current methods and technologies for biological therapeutics. Both have insightful viewpoints of their trade, with the CSO closely working in the world of both academic and industrial research for development of drug products from conception to commercialization.

Read More

LNPs, analytics and mRNA

Working toward advanced analytical techniques

Guten tag from Berlin! As an analytically minded-person, it’s fascinating to connect with colleagues from around the world to discuss cutting-edge techniques and strategies for ensuring the quality, efficacy, and safety of mRNA-based therapeutics. That fascination led me to the mRNA Analytical Development Summit, held in Germany's capital city.

Read More

Climbing Towards the mRNA Summit

Celebrating the work ahead

On my flight to Boston for the mRNA-Based Therapeutics Summit, I followed my usual routine as an uneasy flier; put headphones on and tune out until landing. This time, however, the music continued as I found certain lyrics of one particular song repeating in my mind throughout the two-day gathering of industry leaders:
Read More

Webinar: Comprehensive GMP Manufacturing of mRNA-LNP Drug Products

Streamlining the mRNA manufacturing process from Sequence-to-Vial

The manufacture and release of mRNA therapeutics and vaccines is a complex and challenging process requiring a high degree of expertise, capabilities, and experience. The development and manufacturing of final drug product involves several stages that include production of cell banks, linear DNA, and mRNA drug substance, with lipid nanoparticle (LNP) formulation/encapsulation and analytical testing at all steps, through aseptic fill/finish.

Read More

Webinar: Aldevron/Repligen Case Study

Validation of mRNA concentration determination using variable pathlength spectroscopy

Analytical testing is a critical factor in the development of mRNA-based therapeutics, while at the same time presenting significant challenges. Pre-clinical and clinical testing are only part of what needs to be included in the development process, with the need to meet regulatory requirements while competing in the marketplace being additional considerations.

Read More

Evaluating Capabilities

Dealing with a maturing industry

In my previous post regarding the differences between capacity and capability, I discussed the point that reasonably successful CDMOs have the capacity to manufacture biomolecules in a reproduceable manner and deliver according to a timeline. However, sometimes clients tend to focus on a near-term timeline when evaluating potential CDMO partners, relegating matters that dictate long-term clinical success to future consideration.

Read More

Presentation: Building a Comprehensive mRNA Production Ecosystem

Aiming to eliminate unnecessary complexity

The manufacture and release of mRNA therapeutics and vaccines is a complex and challenging process that requires a high degree of expertise, capabilities, and experience. The production process involves several stages, including the production of cell banks, linear DNA, mRNA drug substance, LNP encapsulation, fill/finish, and analytical testing at each step. Each production stage must be executed with extreme care to ensure the final product's safety and efficacy. 

Read More

An evolution at TIDES

mRNA joins the mix

In the past, the TIDES USA conference event has been focused on oligonucleotide and peptide therapeutics, providing information on development trends and technologies for those industry segments. That is changing now, with an additional focus on mRNA therapeutics coming into the mix. 

Read More

Streamlining the Drug Development Process

Aldevron expands mRNA  production capability

After years of service providers becoming more specialized, we’re now seeing a reversal in that trend. Enterprise offerings and solutions are on the rise, from consumer offerings to huge corporate deals. We can attribute this growth to an increased demand for simplicity of transactions, clear accountability, and building a win-win situation for both parties. 

Read More